       
Acute Myeloid Leukemia (AML)
E2906 Principal Investigator: Larry Schlabach, MD
Co-Investigator: John McCravey, MD and Matt Graham, MD
Title: Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Inductionand Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age ≥ 60 Years) (IRB#: N/A)
NCT #: NCT01041703 Phase: Phase III
Purpose:This randomized phase III trial is studying clofarabine to see how well it works compared with daunorubicin hydrochloride and cytarabine when followed by decitabine or observation in treating older patients with newly diagnosed acute myeloid leukemia.
Drugs possibly given:
Clofarabine
Cytarabine
Daunorubicin hydrochloride
Decitabine
Please view complete information about this trial at: http://www.clinicaltrial.gov/ct2/show/NCT01041703?term=E2906&rank=1
|
